NCT05508074 - Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

November 14, 2024

Study Completion Date

January 20, 2025

Conditions

Amyotrophic Lateral SclerosisALS

Interventions

DRUG

IFB-088 50mg/day

Tested product

DRUG

Placebo

DRUG

Riluzole 100mg/day

Standard of care treatment, co-administered with tested product (IFB-088 50mg/day) or placebo

Trial Locations (9)

APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA, Marseille

IRCSS Istituto Neurologico Carlo Besta, Milan

Centro Clinico NeMO per le Malattie Neuromuscolari, Gussago

CHU de Toulouse - Hôpital Pierre-Paul Riquet, Toulouse

CHU Bretonneau, Tours

Ospedale Civile Sant'Agostino Estense, Baggiovara

CHU de Nantes - Hôpital Laennec, Nantes

Hôpital Neurologique Pierre Wertheimer, Bron

Sant'Andrea Hospital Unit of Neuromuscular Disorders, Roma